Factors associated with willingness to take extended release naltrexone among injection drug users

Keith Ahamad, M. J. Milloy, Paul Nguyen, Sasha Uhlmann, Cheyenne Johnson, Philip (Todd) Korthuis, Thomas Kerr, Evan Wood

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients. Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment. The willingness of opioid-addicted patients to take XR-NTX has not been well described.

METHODS: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with willingness to take the medication.

RESULTS: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1%) were willing to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] = 1.53; 95% confidence interval [CI] = 1.02-2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95% CI = 0.43-0.82). Satisfaction with agonist therapy (13.4%) and unwillingness to stop opioids being used for pain (26.9%) were the most common reasons for being unwilling to take XR-NTX.

CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.

Original languageEnglish (US)
Pages (from-to)12
Number of pages1
JournalAddiction science & clinical practice
Volume10
DOIs
StatePublished - 2015

Fingerprint

Naltrexone
Drug Users
Opioid Analgesics
Injections
Heroin
Odds Ratio
Confidence Intervals
Therapeutics
Narcotic Antagonists
Methadone
Canada
Logistic Models
Pain
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Factors associated with willingness to take extended release naltrexone among injection drug users. / Ahamad, Keith; Milloy, M. J.; Nguyen, Paul; Uhlmann, Sasha; Johnson, Cheyenne; Korthuis, Philip (Todd); Kerr, Thomas; Wood, Evan.

In: Addiction science & clinical practice, Vol. 10, 2015, p. 12.

Research output: Contribution to journalArticle

Ahamad, Keith ; Milloy, M. J. ; Nguyen, Paul ; Uhlmann, Sasha ; Johnson, Cheyenne ; Korthuis, Philip (Todd) ; Kerr, Thomas ; Wood, Evan. / Factors associated with willingness to take extended release naltrexone among injection drug users. In: Addiction science & clinical practice. 2015 ; Vol. 10. pp. 12.
@article{23f4b4ff97914b879869d156d89cb132,
title = "Factors associated with willingness to take extended release naltrexone among injection drug users",
abstract = "BACKGROUND: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients. Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment. The willingness of opioid-addicted patients to take XR-NTX has not been well described.METHODS: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with willingness to take the medication.RESULTS: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1{\%}) were willing to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] = 1.53; 95{\%} confidence interval [CI] = 1.02-2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95{\%} CI = 0.43-0.82). Satisfaction with agonist therapy (13.4{\%}) and unwillingness to stop opioids being used for pain (26.9{\%}) were the most common reasons for being unwilling to take XR-NTX.CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.",
author = "Keith Ahamad and Milloy, {M. J.} and Paul Nguyen and Sasha Uhlmann and Cheyenne Johnson and Korthuis, {Philip (Todd)} and Thomas Kerr and Evan Wood",
year = "2015",
doi = "10.1186/s13722-015-0034-5",
language = "English (US)",
volume = "10",
pages = "12",
journal = "Addiction science & clinical practice",
issn = "1940-0632",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Factors associated with willingness to take extended release naltrexone among injection drug users

AU - Ahamad, Keith

AU - Milloy, M. J.

AU - Nguyen, Paul

AU - Uhlmann, Sasha

AU - Johnson, Cheyenne

AU - Korthuis, Philip (Todd)

AU - Kerr, Thomas

AU - Wood, Evan

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients. Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment. The willingness of opioid-addicted patients to take XR-NTX has not been well described.METHODS: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with willingness to take the medication.RESULTS: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1%) were willing to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] = 1.53; 95% confidence interval [CI] = 1.02-2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95% CI = 0.43-0.82). Satisfaction with agonist therapy (13.4%) and unwillingness to stop opioids being used for pain (26.9%) were the most common reasons for being unwilling to take XR-NTX.CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.

AB - BACKGROUND: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients. Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment. The willingness of opioid-addicted patients to take XR-NTX has not been well described.METHODS: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with willingness to take the medication.RESULTS: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1%) were willing to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] = 1.53; 95% confidence interval [CI] = 1.02-2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95% CI = 0.43-0.82). Satisfaction with agonist therapy (13.4%) and unwillingness to stop opioids being used for pain (26.9%) were the most common reasons for being unwilling to take XR-NTX.CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.

UR - http://www.scopus.com/inward/record.url?scp=84964698903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964698903&partnerID=8YFLogxK

U2 - 10.1186/s13722-015-0034-5

DO - 10.1186/s13722-015-0034-5

M3 - Article

VL - 10

SP - 12

JO - Addiction science & clinical practice

JF - Addiction science & clinical practice

SN - 1940-0632

ER -